8.14  -0.87 (-9.66%)		11-10 16:00
Open: 8.77 High: 9 Volume: 23,003		Pre. Close: 9.01 Low: 8.14 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	33.38	1-year :	48.82
Resists	First :	28.57	Second :	41.79
Pivot price	11.42
Supports	First :	7.19	Second :	5.98
MAs	MA(5) :	9.04	MA(20) :	12.27
	MA(100) :	8.95	MA(250) :	11.54
MACD	MACD :	-0.5	Signal :	0.2
%K %D	K(14,3) :	4.7	D(3) :	3.8
RSI	RSI(14): 39.2
52-week	High :	48.29	Low :	5.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ QNRX ] has closed above bottom band by 11.2%. Bollinger Bands are 121.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 21 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	9.03 - 9.08	9.08 - 9.12
Low:	8 - 8.06	8.06 - 8.12
Close:	8.04 - 8.14	8.14 - 8.22

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Thu, 06 Nov 2025
Quoin Pharmaceuticals Ltd reports results for the quarter ended September 30 - Earnings Summary - TradingView

Thu, 06 Nov 2025
Quoin Pharmaceuticals Closes $105.3 Million Private Placement and Expands Pediatric Netherton Syndrome Program with FDA Orphan Drug Designation - Quiver Quantitative

Thu, 06 Nov 2025
Quoin (NASDAQ: QNRX) reports Q3; FDA orphan drug for QRX003; $105.3M financing - Stock Titan

Thu, 30 Oct 2025
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Sahm

Tue, 28 Oct 2025
Quoin Pharmaceuticals Ltd stock climbs on encouraging pediatric trial results - MSN

Tue, 21 Oct 2025
Quoin (NASDAQ: QNRX) secures FDA Orphan Drug Designation for QRX003 in Netherton Syndrome - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	4 (M)
Held by Insiders	9.4 (%)
Held by Institutions	5.5 (%)
Shares Short	80 (K)
Shares Short P.Month	4 (K)

EPS	958.65
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-69.1 %
Return on Equity (ttm)	-242.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-20.86
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	1.87
Price to Sales	0
Price to Cash Flow	-0.46

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.